CBX7 and acute myeloid leukemia: To determine whether CBX7 inhibitors reduced the survival of primary AML cells we exposed multiple patient-derived AML samples (see supplemental Table 2 for patient information and supplemental Figure 6A for CBX7 expression levels) to the inhibitors MS452, EC-134, and BDA-41.